{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:26:31Z","timestamp":1789014391733,"version":"build-2803163510"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>To review the pharmacology, efficacy, safety, dosing and administration, and place in therapy of asciminib, an oral tyrosine kinase inhibitor (TKI) used as a third-line treatment option for Philadelphia chromosome\u2013positive chronic myeloid leukemia (CML) in chronic phase.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>CML is a rare cancer caused by a chromosomal translocation that forms a fusion of the BCR and ABL1 genes on chromosomes 22 and 9. Until recently, patients for whom first-line treatment options failed were treated with TKIs that bind to the adenosine triphosphate\u2013binding site on BCR-ABL1. However, because of similar mechanisms of action, there continues to be an unmet need in patients for whom at least 2 TKIs have failed or those with a T315I mutation unable to tolerate ponatinib. In October 2021, the Food and Drug Administration approved asciminib (Scemblix), the first TKI specifically targeting the ABL1 myristoyl pocket (STAMP) via allosteric binding, as a third-line option for patients with chronic-phase (CP)-CML. Asciminib received accelerated approval due to meeting its primary endpoint at week 24, demonstrating a major molecular response rate of 25.5% for patients on asciminib compared to 13.2% for those receiving bosutinib. In addition, patients on asciminib achieved a higher rate of complete cytogenetic response at 40.8% compared to a rate of 24.2% for bosutinib. Clinicians prescribing asciminib should monitor for increased levels of pancreatic enzymes, hypertension, cardiovascular toxicity including ischemic and thromboembolic conditions, and decreased numbers of neutrophils and platelets, as these may require treatment interruption, dose reduction, or treatment discontinuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Asciminib is a unique targeted TKI that provides clinicians with an additional third-line and beyond treatment option for adults with CP-CML regardless of mutation status as well as a second TKI treatment option for patients harboring a T315I mutation.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxac286","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T17:58:45Z","timestamp":1664992725000},"page":"36-43","source":"Crossref","is-referenced-by-count":7,"title":["Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation"],"prefix":"10.1093","volume":"80","author":[{"given":"Shanada","family":"Monestime","sequence":"first","affiliation":[{"name":"Miami Cancer Institute, Baptist Health South Florida , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiba","family":"Al Sagheer","sequence":"additional","affiliation":[{"name":"Miami Cancer Institute, Baptist Health South Florida , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tadros","sequence":"additional","affiliation":[{"name":"Miami Cancer Institute, Baptist Health South Florida , Miami, FL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"2023010802113499800_CIT0001","article-title":"Chronic myelogenous leukemia","volume-title":"StatPearls","author":"Eden","year":"2022"},{"key":"2023010802113499800_CIT0002","volume-title":"Cancer Facts & Figures 2022","author":"American Cancer Society.","year":"2022"},{"key":"2023010802113499800_CIT0003","author":"SEER"},{"key":"2023010802113499800_CIT0004","author":"National"},{"issue":"9","key":"2023010802113499800_CIT0005","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1038\/leu.2015.152","article-title":"Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib","volume":"29","author":"Castagnetti","year":"2015","journal-title":"Leukemia"},{"issue":"5","key":"2023010802113499800_CIT0006","doi-asserted-by":"crossref","first-page":"e468","DOI":"10.1097\/HS9.0000000000000468","article-title":"Chronic myeloid leukemia in 2020","volume":"4","author":"Hehlmann","year":"2020","journal-title":"Hemasphere"},{"issue":"1","key":"2023010802113499800_CIT0007","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","article-title":"Third-line therapy for chronic myeloid leukemia: current status and future directions","volume":"14","author":"Cortes","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"18","key":"2023010802113499800_CIT0008","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem"},{"issue":"7647","key":"2023010802113499800_CIT0009","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"issue":"suppl 1","key":"2023010802113499800_CIT0010","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1182\/blood-2018-99-113609","article-title":"Asciminib, a specific allosteric BCR-ABL1 inhibitor, in patients with chronic myeloid leukemia carrying the T315I mutation in a phase 1 trial","volume":"132","author":"Rea","year":"2018","journal-title":"Blood"},{"key":"2023010802113499800_CIT0011","volume-title":"Package insert","author":"Scemblix (asciminib).","year":"2021"},{"issue":"24","key":"2023010802113499800_CIT0012","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"2023010802113499800_CIT0013","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/leu.2016.353","article-title":"Identification and characterization of activating ABL1 1b kinase mutations: impact on sensitivity to ATP-competitive and allosteric ABL1 inhibitors","volume":"31","author":"Lee","year":"2017","journal-title":"Leukemia"},{"issue":"21","key":"2023010802113499800_CIT0014","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood.2020009984","article-title":"A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"key":"2023010802113499800_CIT0015","volume-title":"Package insert","author":"Bosulif (bosutinib).","year":"2020"},{"key":"2023010802113499800_CIT0016"},{"issue":"22","key":"2023010802113499800_CIT0017","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med"},{"issue":"4","key":"2023010802113499800_CIT0018","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2023010802113499800_CIT0019","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-139677","article-title":"Asciminib, a first-in-class STAMP inhibitor, provides durable molecular response in patients (pts) with chronic myeloid leukemia (CML) harboring the T315I mutation: primary efficacy and safety results from a phase 1 trial","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"issue":"21","key":"2023010802113499800_CIT0020","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1182\/blood.2021012082","article-title":"Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"2023010802113499800_CIT0021","volume-title":"Package insert","author":"Iclusig (ponatinib).","year":"2012"},{"key":"2023010802113499800_CIT0022","author":"Takeda"},{"key":"2023010802113499800_CIT0023","year":"2022"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac286\/46544331\/zxac286.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/2\/36\/48415819\/zxac286.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/80\/2\/36\/48415819\/zxac286.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,8]],"date-time":"2023-01-08T02:14:10Z","timestamp":1673144050000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/80\/2\/36\/6748956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,5]]},"published-print":{"date-parts":[[2023,1,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac286","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,15]]},"published":{"date-parts":[[2022,10,5]]}}}